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Summary
Breast cancer is the most common cancer in women. Early breast cancer is potentially curable disease. Systemic adju-
vant therapy is created to treat micrometastatic disease or destroy breast cancer cells that have spread from the breast and 
regional lymph nodes, but have not yet formed visible distant metastases. Systemic adjuvant therapy is based on chemo-
therapy with or without targeted therapy, and endocrine therapy, sometimes in combination with adjuvant irradiation, 
usually is conducted after surgery. The aim of adjuvant therapy is to decrease recurrence rate and extension of overall sur-
vival.
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SUSTAVNO ANTINEOPLASTIČNO LIJEČENJE RAKA DOJKE
Sažetak
Rak dojke najčešća je zloćudna bolest u žena, potencijalno izlječiva u ranom stadiju. Sustavno adjuvantno liječenje 
osmišljeno je za uništenje mogućih mikrometastaza  proširenih iz dojke i/ili iz regionalnih limfnih čvorova, koje još nisu 
 stvorile vidljive udaljene metastaze. Temelji se na kemoterapiji sa ili bez ciljane biološke terapije, na endokrinoj terapiji, 
ponekad u kombinaciji sa zračenjem, obično nakon kirurškog zahvata. Cilj je smanjiti stopu povratka bolesti i produžiti 
život bolesnika.
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Breast cancer is the major public health prob-
lem both in the world and in Croatia. It is the most 
common cancer in women and in 2011 the in-
cidence in Croatia was about 94.4 new cases per 
100 000, which is higher than in the European 
Union (68.8/100 000). Breast cancer is also the lead-
ing cause of dea th from malignancy in women 
with an annual rate of 40.3 cases per 100 000, while 
the mortality rate in the EU is almost twice as low 
(24.8/100 000) (1).
Introduction of mammography  screening 
programs contributed to the increase in the num-
ber of newly diagnosed cases of breast cancer in 
the world and it led to the detection of breast can-
cer in an earlier stage. High mortality rate from 
breast cancer in Croatia is possibly consequence of 
a poor response to the national mammography 
program for early detection of breast cancer. The 
response has decreased by approximately 25% in 
the last few years. Around 70 000 preventive ex-
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aminations of the breast were done in 2010, while 
in 2012 that fi gure decreased to about 50 000 (2).
Mortality from breast cancer in the devel-
oped world is decreasing which is not the case in 
Croatia (3). There are many factors which infl u-
ence the prognosis of breast cancer, such as: axil-
lary lymph node status, primary tumor size, pres-
ence of lymphovascular and perineuralinvasion, 
age, histological grade, tumor subtype, response 
to the primary neoadjuvant treatment, hormone 
receptor status and the presence of HER2 gene 
amplifi cation. Number of involved axillary lymph 
nodes correlates with probability of cancer spread 
to the distant organs.
Patients with breast cancer which has not 
spread to the axilla have the overall 10-year sur-
vival rate of about 70%, while the 5-year disease 
recurrencerate in these patients is about 19%. In 
patients with positive axillary lymph nodes 5-year 
disease recurrence rate is 30% to 40% if they have 
1 to 3 positive lymph nodes, 44% to 70% if they 
have 4 to 9 positive lymph nodes, and 72% to 82% 
if they have more than 10 positive nodes.
In order to reduce the probability of disease 
recurrence and death from breast cancer in pa-
tients in whom the disease was diagnosed in an 
early stage, adjuvant systemic antineoplastic treat-
ment alone or in combination with adjuvant irra-
diation is applied after surgical procedure.
Adjuvant treatment of breast cancer is de-
signed to treat micrometastatic disease or destroy 
breast cancer cells that have spread from the breast 
and regional lymph nodes, but have not yet for-
med visible distant metastases. Depending on the 
applied model of risk reduction, it is estimated 
that adjuvant treatment reduces mortality rates by 
35% to 72%.
King and his colleagues proved a low rate of 
occult contralateral breast cancer cases and based 
on their study contralateral prophylactic mastec-
tomy in average risk patients with newly diag-
nosed breast cancer is not recommended (4).
Standard adjuvant chemotherapy treatment 
includes a combination of cytotoxic drugs, i.e. po-
lychemotherapy. Numerous clinical studies have 
shown that the use of adjuvant chemotherapy 
prolongs overall survival without disease recur-
rence, which is especially noted in hormone-inde-
pendent disease, while the use of endocrine thera-
py prolongs overall and disease-free survival in 
patients with hormone-dependent tumors (5, 6).
The decision to use adjuvant treatment 
should be individualized and depend on the char-
acteristics of patient and tumor, and should con-
sider patients’comorbidities. It should be the re-
sult of teamwork. When making decision about 
systemic treatment, the most important prognos-
tic factors are patient’sage, primary tumor size, 
grade, number of involved axillary lymph nodes 
and HER2 status (7). HER2 status is particularly 
important prognostic factor in patients with nega-
tive axillary lymph nodes (8). Today, there are 
methods which can, based on determining the ge-
netic profi le using the RT-PCR (Oncotype DX) or 
microarrays technology(MammaPrint), assess the 
risk of recurrence and predict the response to che-
motherapy and endocrine therapy. Use of Onco-
type DX and MammaPrint was evaluated in sev-
eral studies and it was proved to be useful in pre-
dicting benefi t from the addition of chemotherapy 
to endocrine therapy (9).
National Comprehensive Cancer Network 
(NCCN) guidelines for use of adjuvant systemic 
therapy are based on information about the size of 
the primary tumor, axillary lymph node status, 
hormone receptor status and HER2 gene amplifi -
cation.Those guidelines does not recommend as-
sessment of Ki67 as there is no conclusive evidence 
that Ki67 helps selecting the type of adjuvant ther-
apy for individual patient.
On the contrary, European Society of Medi-
cal Oncology (ESMO) guidelines for breast cancer 
consider determining of Ki67 as one of the most 
important parameters.
For tumors smaller than 5 mm, which have 
notspread to axillary lymph nodes, the use of ad-
juvant therapy is of litt le importance. The use of 
endocrine therapy in patients with hormone-de-
pendent tumors may be considered in terms of re-
ducing the risk of developing contralateral breast 
cancer.
Patients with tumors size between 6 mm and 
10 mm, which have not spread to the axillary 
lymph nodes, can be divided into low-risk and 
high-risk group. High-risk patients are those whose 
tumors show HER2 gene amplifi cation, are hor-
mone-independent, are high-grade and/or show 
lymphovascular or perineural invasion. In this 
group the decision on the type of therapy that will 
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be applied depends on the preference of the pa-
tient and balancing between the benefi ts and 
harms of therapy.
Patients with positive axillary lymph nodes 
or tumors larger than 10 mm are candidates for 
adjuvant systemic therapy. Patients with hormo-
ne-independent tumors larger than 10 mm and 
negative axillary lymph nodes are candidates for 
application of adjuvant chemotherapy. Patients 
with hormone-dependent tumors larger than 10 
mm and negative axillary lymph nodes are candi-
dates for adjuvant endocrine therapy and chemo-
therapy, however, in this group, the benefi t of che-
motherapy is relatively small (6).
Genetic profi ling using Oncotype DX may be 
recommended to patients with hormone-depen-
dent breast cancer larger than 10 mm, which 
shows no amplifi cation of HER2, patients with 
grade 2 or 3 hormone-dependent tumors size be-
tween 6 mm and 10 mm, and patients whose tu-
mor expresses other characteristics that indicate 
high risk (5,10,11).
According to the 2011 and 2013 St. Gallen 
guidelines the decision on the application of adju-
vant chemotherapy depends, among other things, 
on the value of Ki67, which is one of the key ele-
ments in determining luminal subtype A and B in 
hormone-dependent tumors. According to Euro-
pean guidelines application of adjuvant chemo-
therapy is not indicated in almost all luminal A 
cases (ER positive, HER2 negative, Ki67<20%, 
PR>20%) except forhigh-risk tumors (tumor cells 
innumerous axillary lymph nodes). Eff ectiveness 
of chemotherapy is also unclear in the cases of lu-
minal HER2 negative tumors (ER positive, HER2 
negative and Ki67>20% or PR<20%) (11). Inthese 
groups of patients, genetic profi ling may be per-
formed to accurately assess potential benefi ts of 
application of adjuvant chemotherapy.
All patients with invasive, hormone-depen-
dent breast cancer should receive adjuvant, post-
operative, protective, endocrine therapy regard-
less of age, menopausal status, axillary lymph 
node status or the application of chemotherapy 
(13). Possible exception to this rule, could be a 
group of patients with hormone-dependent breast 
cancer smaller than 5 mm with negative axillary 
lymph nodes which shows good prognostic fea-
tures because, in this group,long-term prognosis 
is so good that the benefi t of adjuvant endocrine 
therapy is very small (6).
Based on retrospective analysis of paraffi  n 
tumor blocks collected in the ATAC study, it was 
proven that the presence of HER2 gene amplifi ca-
tion indicates relative resistance to the use of en-
docrine therapy (14). However, in patients with 
HER2-positive and hormone-dependent tumors 
use of endocrine therapy is recommended.
The longest used and best researched endo-
crine therapy for premenopausal and postmeno-
pausal women istamoxifen (9). Regardlessof ap-
plication of adjuvant chemotherapy, prophylactic 
use of tamoxifen reduces the risk of recurrence 
and death from breast cancer. If patients are re-
ceiving chemotherapy and tamoxifen, chemother-
apy is administered fi rstand is followed by tamox-
ifen (12). Numerous studies have shown that the 
use of tamoxifen for fi ve years is more eff ective 
than the use for one to two years (14,15). Recently, 
the ATLAS study showed that prolonged use of 
tamoxifen for ten years compared to the standard 
use for fi ve years reduces the risk of death from 
breast cancer, though we have to be aware of 
 increased risk of endometrial cancer and pulmo-
nary embolism (16). We are expecting the results 
of aTTom study whichalso compared standard 
fi ve-year toten-yeartamoxifentherapy. Prelimi-
nary results indicate a non-signifi cant reduction of 
local recurrence rate with ten-year treatment (17).
The role of ablation or suppression of ovarian 
function in adjuvant, postoperative, prophylactic 
treatment of breast cancer, whether we are refer-
ring to a surgical oophorectomy, irradiation or 
suppression using the LHRH agonists, has not yet 
been clearly defi ned (18-20). Although individual 
studies suggest clinical benefi t from ablation or 
suppression of ovarian function in the adjuvant 
treatment of premenopausal patients with hormo-
ne-dependent breast cancer, the benefi t of the ad-
dition of the aforementioned modalities of treat-
ment to chemotherapy or tamoxifen is not clear or 
proven (19,21).
Several studies have compared the suppres-
sion of ovarian function with CMF chemotherapy 
protocol, and it was observed that in patients with 
hormone-dependent breast cancer antitumor ac-
tivity of both modalities was equal, while in pa-
tients with hormone-independent breast cancer 
greater benefi t was achieved by the use of chemo-
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therapy. It was also observed thatt he younger pre-
menopausal women had the greater benefi t of 
suppressing ovarian function (21-29). None of 
these studies showed diff erence in the disease re-
currence rate or survival rate (19,30,31).
Intergroup 0101 study compared the applica-
tion of adjuvant chemotherapy with CAF protocol 
with CAF plus goserelin and CAF plus goserelin 
plus tamoxifen. It was observed that the addition 
of goserelin to chemotherapy extended the time to 
recurrence in comparison with chemotherapy 
only, but did not infl uence overall survival. This 
study, unfortunately, did not include a study group 
that received CAF plus tamoxifen, so the extent to 
which the use of goserelin prolongs the time to re-
currence compared to standard endocrine therapy 
with tamoxifen,could not be assessed (22).
Several studies have investigated the appli-
cation of aromatase inhibitors in the adjuvant 
treatment of postmenopausal patients with early 
breast cancer. Aromatase inhibitors in the adju-
vant treatment may be administered as the initial 
therapy, as sequential therapy after two to three 
years of tamoxifen or as extended adjuvant thera-
py after 4.5 to 6 years of tamoxifen therapy.
There was no diff erence in survival between 
patients who received aromatase inhibitors as ini-
tial therapy compared to patients who received 
tamoxifen (32,33). ATAC study, however, showed 
that patients who initially received adjuvant en-
docrine therapy with anastrozole, had fewer cases 
of disease recurrence compared to patients initial-
ly receiving tamoxifen (32).
BIG 1-98 study investigated the initial and se-
quential treatment with an aromatase inhibitor 
compared to treatment with tamoxifen and show-
ed that patients receiving letrozole had a pro-
longed time to relapse compared to those treated 
only with tamoxifen, but without aff ecting the 
overall survival (34).
Five studies investigated sequential use of 
third generation aromatase inhibitor after two to 
three years of treatment with tamoxifen. Studies 
that investigated the application of anastrozole 
(ITA, ABCSG trial 8, ARNO 95) after two to three 
years of adjuvant therapy with tamoxifen showed 
a prolongation of disease-free survival, and some 
of them the extension of overall survival, which 
was demonstrated by a meta-analysis of these 
three studies (35-38).
IES study showed that sequential use of ex-
emestane after two to three years of tamoxifen 
prolongs disease-free survival and overall surviv-
al (39,40).
TEAM study compared the application of ex-
emestane as initial therapy with sequential appli-
cation of exemestane after two to three years of 
tamoxifen therapy, up to a total of 5 years of use 
(41). Results of this study are consistent with the 
results of the BIG 1-98 and they suggest that none 
of the described methods of application of adju-
vant endocrine therapy is superior to another (34).
MA-17 study showed that prolonged therapy 
with letrozole after 4.5 to 6 years of tamoxifen re-
duces disease recurrence rate and occurrence of 
contralateral breast cancer, while in the group of 
patients with positive lymph nodes also prolongs 
overall survival (35,42).
Today we can not defi nitely say which model 
of adjuvant endocrine treatment is optimal - is it 
the initial application of aromatase inhibitor in 
postmenopausal patients, sequential use of tamox-
ifen and aromatase inhibitor or prolonged therapy 
with an aromatase inhibitor after about fi ve years 
of adjuvant tamoxifen therapy. Also, it is still un-
clear what is the optimal duration of therapy with 
an aromatase inhibitor.
Recommendations for adjuvant treatment of 
postmenopausal patients at the time of diagnosi-
sare: 1) an aromatase inhibitor as initial therapy 
for 5 years, 2) tamoxifen during two to three years 
followed by sequential administration of an aro-
matase inhibitor to a total of 5 years or use of an 
aromatase inhibitor for additional 5 years (least 
evidence of effi  ciency), 3) tamoxifen during 4.5 to 
6 years followed by a prolonged treatment with an 
aromatase inhibitor over 5 years (if initially pre-
menopausal patient becomes postmenopausal over 
the 5 years) or consider taking tamoxifen over 
 total of 10 years (if the patient is initially preme-
nopausal), taking into account the wishes of the 
patients.
Adjuvant chemotherapy is applied in order 
to prolong overall and disease-free survival. Adju-
vant chemotherapy should be started within 2 to 6 
weeks after the surgery because the literature data 
show a signifi cant decrease in eff ectiveness when 
the application of adjuvant systemic therapy is 
postponed for more than 12 weeks after the sur-
gery (43).
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According to the National Comprehensive 
Cancer Network (NCCN) guidelines preferred 
adjuvant chemotherapeutic protocols for the treat-
ment of breast cancer include: 1) dose-dense (com-
mon application) AC (doxorubicin, cyclophospha-
mide) with sequential use of dose-dense paclitaxel 
(every 2 weeks); 2) dose-dense AC with sequential 
use of weekly paclitaxel; 3) docetaxel and cyclo-
phosphamide combination.
Two large randomized studies that have ex-
amined the addition of sequential paclitaxel to ad-
juvant chemotherapy with AC protocol in the pa-
tients with positive lymph nodes showed thep-
rolongation of disease-free survival and overall 
survival. The advantage of paclitaxel was more 
expressed in patients with hormone-independent 
breast cancer (44,45). Besides preferred protocols, 
there are other protocols that may be applied in 
adjuvant treatment, depending on the characteris-
tics of the patient, characteristics of the tumor and 
the patient wishes. All protocols listed and de-
scribed below have been tested in randomized 
phase 3 clinical trials.
Large randomized study on almost 5000 pa-
tients who were classifi ed into four groups (AC 
followed by a weekly paclitaxel/docetaxel or pa-
clitaxel/docetaxel every 3 weeks) showed that; pa-
clitaxel is most eff ective when used on a weekly 
basis - it prolongs overall survival compared to 
paclitaxel every 3 weeks; the use of docetaxel ev-
ery 3 weeks is more eff ective compared to pacli-
taxel every 3 weeks or weekly docetaxel which 
prolongs disease-free survival,does not aff ect 
overall survival, but it is still less effi  cient com-
pared to weekly paclitaxel (46).
Other study that examined adjuvant chemo-
therapy with dose-dense AC followed by pacli-
taxel every 2 weeks showed a prolongation of sur-
vival in comparison with AC protocol followed by 
paclitaxel every 3 weeks (47).
Based on these two studies the application of 
paclitaxel every 3 weeks after AC in the adjuvant 
treatment is not recommended in any guideline.
A study that compared adjuvant treatment 
with TC protocol (docetaxel, cyclophosphamide) 
with AC protocol has proved that the TC protocol 
signifi cantly prolongs disease-free survival and 
overall survival compared to AC protocol (48).
It has been shown that there is no diff erence 
in disease-free survival and overall survival be-
tween use of adjuvant chemotherapy with AC 
protocol applied for four cycles and CMF (cyclo-
phosphamide, methotrexate, 5-fl uorouracil) pro-
tocol applied for six cycles (48-50).
Application of CMF chemotherapy signifi -
cantly prolongs disease-free and overall survival 
in comparison with observation (5,51).
Studies that investigated adjuvant anthracy-
cline-based chemotherapy have shown that it re-
duces the rate of disease recurrence and death 
from breast cancer and is recommended as the 
preferred therapy in patients with positive axil-
lary lymph nodes. Those studies also emphasize 
the importance of applying the full dose of cyto-
toxic drugs (51,52).
Retrospective studies have shown that adju-
vant anthracycline-based chemotherapy is more 
eff ective in patients with HER2-positive tumors 
compared to non-anthracycline-based chemother-
apy (8).
One large study compared high dose CEF (cy-
clophosphamide, epirubicin 100 mg/m2, 5- fl uoro-
uracil) chemotherapy with CMF protocol in pre-
menopausal patients with breast cancer and posi-
tive axillary lymph nodes. Results of this study 
showed a signifi cant prolongation of survival with-
out recurrence and overall survival in patients who 
received CEFas adjuvant therapy (53).
One study compared adjuvant FEC protocol 
for six cycles with three cycles of FEC followed by 
three cycles of docetaxel every 3 weeks in patients 
with positive lymph nodes and high-risk patients 
with negative lymph nodes. A group of patients 
who received docetaxel sequentially after FEC 
had signifi cantly longer disease-free survival and 
overall survival (54).
It was also proven that the use of weekly pa-
clitaxel after FEC is superior to the standard six 
cycles ofFEC in terms of reducing the risk of dis-
ease recurrence, but with no eff ect on overall sur-
vival (55).
When comparing adjuvant chemotherapy 
with TAC protocol (docetaxel, doxorubicin,  cyclo-
phosphamide)in patients with positive axillary 
lymph nodes with FACprotocol (5-fl uorouracil, 
doxorubicin, cyclophosphamide), it has been pro-
ven that TAC signifi cantly prolongs overall and 
disease-free survival. It is important to emphasize 
that the disease-free survival was the same in pa-
Libri Oncol., Vol. 42 (2014), No 1–3, 41 – 50
46
tients with hormone-dependent and hormone-in-
dependent tumors (56).
NSABP B-30 study compared TAC with AT 
(doxorubicin, docetaxel) and AC-T (doxorubicin, 
cyclophosphamide - docetaxel) adjuvant proto-
cols. Results of this study showed that AC-T che-
motherapy signifi cantly prolongs disease-free 
survival but not overall survival compared to TAC 
protocol, and compared to AT protocol signifi -
cantly prolongs both overall and disease-free sur-
vival (57).
The eff ect of the application of adjuvant che-
motherapy is more signifi cant in patients with 
hormone-independent breast cancer (5,10).
Therefore, the guidelines recommend con-
sideration of the application of adjuvant chemo-
therapyfollowed by endocrine therapy in patients 
with hormone-dependent breast cancer with neg-
ative axillary lymph nodes, in patients with tu-
mors larger than 10 mm which are HER2 negative 
and in patients with tumors between 6 mm and 10 
mm, grade 2 or 3 or if tumor showsnegative prog-
nostic features.
In patients whose tumors show HER2 pro-
tein overexpression, the addition of trastuzumab 
to adjuvant treatment signifi cantly prolonged dis-
ease-free survival as well as overall survival (58). 
Trastuzumab is a humanized monoclonal anti-
body that specifi cally binds to the extracellular 
domain of the HER2 protein (59).
The NSABP B-31 study included patients 
with HER2-positive breast cancer who had posi-
tive axillary lymph nodes. Patients were random-
ized to receive AC during four cycles every 3 
weeks followed by paclitaxel every 3 weeks for 
four cycles or to receive four cycles of AC followed 
by paclitaxel plus trastuzumab for four cycles, fol-
lowed by trastuzumab alone for a total of one 
year.
The NCCTG N9831 trial enrolled patients 
with HER2-positive breast cancer who had posi-
tive axillary lymph nodes,patients who had nega-
tive axillary lymph nodes with primary hormone-
independent tumor bigger than 10 mm and pa-
tients whose primary hormone-dependent tumor 
was larger than 20 mm. Patients were randomized 
similar to NSABP B-31 study except that paclitaxel 
was administered at weekly intervals for 12 weeks. 
In the subgroup of patients who received trastu-
zumab, it was administered together with pacli-
taxel and then once a week up to a total of 52 
weeks.
Both of these studies showed a signifi cant re-
duction of risk of disease recurrence and death 
from breast cancer by adding trastuzumabto adju-
vant chemotherapy treatment (60). It is important 
to emphasize that in both studies patients who 
were treated with trastuzumab have had an in-
creased rate of cardiotoxicity. However, cardio-
toxicity was dependent on patients’ age and initial 
cardiac systolic function. Increased rate of cardio-
toxicity observed in adjuvant trials with trastu-
zumab was partly a consequence of pretentious 
cardiac function monitoring in these studies.
The third study that examined the eff ective-
ness of trastuzumab in the adjuvant treatment was 
HERA study which compared the application of 
trastuzumab for one or two years. The patients in-
cluded in this study had either positive or nega-
tive axillary lymph nodes with primary tumor 
larger than 10 mm (61). After a median follow-up 
of one year 46% reduction in the risk of recurrence 
was recorded. After a median follow-up of two 
years a signifi cant diff erence in overall survival 
was recorded (62). After that moment, the patients 
who were primarily randomized to receive che-
motherapy alone were allowed to cross over and 
to receive trastuzumab subsequently. After a me-
dian follow-up of eight years there was no signifi -
cant diff erence in disease-free survival between 
patients who received trastuzumab for one and 
two years (63). Therefore, the standard time of ap-
plication of adjuvant trastuzumab is one year.
The BCIRG 006 trial enrolled women with 
HER2-positive breast cancer with positive axillary 
lymph nodes or high-risk women with negative 
lymph nodes. Patients were randomized to re-
ceive either the AC followed by docetaxel (AC-T) 
or AC followed by docetaxel with trastuzumab 
(AC-TH) and then trastuzumab monotherapy du-
ring one year or were randomized to receive 
docetaxel, carboplatin and trastuzumab (TCH) up 
to a total of one year of trastuzumab (58). In both 
trastuzumab groups overall survival was longer 
than in the control group. Cardiotoxicity rate was 
signifi cantly lower in the TCH group compared to 
the AC-TH group. In the TCH group slightly high-
er number of distant disease recurrences was 
found compared to the AC-TH group.
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The FinHer study included patients with 
HER2-positive breast tumors and positive axillary 
lymph nodes and patients with negative axillary 
lymph nodes with tumors larger than 2 cm and 
negative progesterone receptors. Patients were 
randomized to receive nine weekly vinorelbine or 
three docetaxel every three weeks, which was fol-
lowed by three cycles of FEC. One part of patients 
in both groups was randomized to receive trastu-
zumab over nine weeks with assigned chemother-
apy protocol – docetaxel or vinorelbine. Results of 
the study showed that the addition of trastuzum-
ab reduces the risk of recurrence, but does not af-
fect overall survival. FinHer is the only study of 
adjuvant trastuzumab, which was sponsored by 
Finland government and not by large pharmaceu-
tical companies, which showed that short adju-
vant trastuzumab treatment does not signifi cantly 
aff ect survival.
Described adjuvant trastuzumab studies have 
shown that its addition to adjuvant treatment sig-
nifi cantly prolongsdisease-free survival. Meta-
analysis of three of these studies (NSABP B-31, 
NCCTG N9831, HERA) revealed that addition of 
trastuzumab also prolongs overall survival in 
high-risk patients with HER2-positive breast can-
cer. The usefulness of trastuzumab is independent 
of the tumor hormone receptor status (64,65,66).
In FNCLCC-PACS-04 study fi ve hundred 
HER2 positive women with positive axillary 
lymph nodes were randomized to receive trastu-
zumab sequentially after adjuvant chemotherapy 
based on anthracycline with or without docetax-
elor just to be observed. Results of the study 
showed no signifi cant prolongation of overall or 
disease-free survival with sequential addition of 
trastuzumab (67). Sequential application of trastu-
zumab after chemotherapy is not eff ective as the 
concomitant chemotherapy with trastuzumab.
NCCN strongly recommends the application 
of trastuzumab together with chemotherapy in 
the adjuvant treatment of breast cancer patients 
with HER2-positive tumors larger than 1 cm and 
in patients with HER2-positive tumors size be-
tween 6 mm and 10 mm, which are associated 
with micrometastasis in the axillary lymph nodes 
(tumor deposit in the axilla smaller than 2mm). 
For smaller tumors application of trastuzumab 
with chemotherapy is a matt er of individual as-
sessment.
Protocols that are recommended in the adju-
vant treatment of HER2 positive disease are AC 
protocol followed by paclitaxel with trastuzumab 
over 12 weeks and TCH protocol in patients at risk 
for developingcardiotoxicity. Also trastuzumab 
can be combined with weekly paclitaxel over 12 
weeks in patients with small tumors and negative 
axillary lymph nodes. Trastuzumab should be 
continued up to one year starting from the fi rst 
dose of taxane chemotherapy.
In addition to the above listed preferred pro-
tocols, AC protocol followed by docetaxel with 
trastuzumab to a total of one year of trastuzumab 
may be also applied in patients with HER2-posi-
tive tumors (58). The use of adjuvant anthracy-
cline-based chemotherapy followed by sequential 
trastuzumabis not recommended (67). Consider-
ing the cumulative cardiotoxicity simultaneous, 
concomitant use of trastuzumab and anthracycli-
nesis not recommended except within clinical 
studies.
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